Zydus Cadila files IND application for NME - ZYH2
New Delhi, Mar 27 (UNI) Cadila Healthcare Ltd today said it has filed an Investigational New Drug (IND) application for the New Molecular Entity, ZYH2, with the Drug Controller General of India.
The novel agent for treating diabetes has been designed and developed by Zydus Research Centre, the research wing of the Company.
'ZY H2', has displayed a unique profile in pre-clinical studies. The NME has the potential to improve insulin resistance and lower blood glucose in diabetic conditions without causing hypoglycemia. It also works favourably to lower the elevated lipid levels.
It is estimated that there are 30 to 33 million diabetics in India now, and every fourth diabetic in the world today is an Indian.
With this filing, Cadila has filed three INDs - ZYH1, ZYH and ZYH2. The NME - ZYH1 has entered phase two clinical trials.
Indians are genetically more susceptible to diabetes and the World Health Organisation (WHO) predicts the number of diabetics in India would go up to 40 million by 2010 and 74 million by 2025, making it the diabetes capital of the world.
UNI SR SS DS1500